by Kelly Irvin
The number one reason to participate in a clinical trial is because someone has to do it so new drugs can be developed to treat and even cure cancer. All of the drugs we have now were … Read more
New research led by investigators at MIT, has demonstrated that a patient’s own live tumor cells, damaged by chemotherapy, may also augment antitumor immunity. The results suggest these live cell adjuvants may enhance the effectiveness of immune checkpoint blockade (ICB)
… Read more— In vitro maturation can result in both embryos and oocyte vitrification, researcher says
by Amanda D’Ambrosio
In vitro maturation of immature eggs may be an effective method of fertility preservation for patients with gynecologic cancers, according to a prospective … Read more
By Kelly Irvin
Health care isn’t something that is done to you. You participate in it. You’re part of the team. If your team is letting you down, say so. If they don’t do better, consider seeking health care providers … Read more
By Krista Conger
It’s diabolical, and so clever. Recent research by cancer biologist Wendy Fantl, PhD, and immunologist and cancer biologist Veronica Gonzalez, PhD, shows that ovarian tumors thrive by convincing nearby immune cells that the cancer cells are those … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
By Mike Bassett
— For those on active therapy, 80% had increased antibody levels, study showed
A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as … Read more
By The ASCO Post Staff
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more
By Mike Bassett
— Programs frequently using this treatment achieved these declines without compromising OS
Cancer programs that were more likely to use neoadjuvant chemotherapy to treat advanced ovarian cancer saw larger declines in short-term mortality versus programs with less … Read more
By Jamie Cesanek
Maintenance therapy is meant to prevent relapse after a patient with ovarian cancer received their main treatment. Here’s an overview of what patients should know.
When a patient is diagnosed with ovarian cancer, their initial treatment typically
By Aatif Sulleyman
A woman is raising awareness of ovarian cancer and how difficult it can be to detect, having been diagnosed with the illness by a dermatologist who removed a small growth from her navel.
Despite being aware of … Read more
By Jessica Nye, PhD
A cross-sectional study found that caregivers of patients with ovarian cancer were experiencing symptoms of depression and anxiety which were affected by attachment avoidance. These findings were published in Current Oncology.
Caregivers are an important … Read more
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the … Read more
By Wistar Institute
Newswise — PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered … Read more
A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.
The combination of drugs – which both work by blocking signals cancer … Read more
In the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among … Read more
— Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed
Patients with relapsed platinum-sensitive ovarian cancer had significant improvement in progression-free survival (PFS) when retreated with the PARP inhibitor olaparib … Read more
By Matthew Stenger
In a Japanese phase III trial (NINJA) reported in the Journal of Clinical Oncology, Hamanishi et al found that nivolumab did not improve overall survival vs chemotherapy with either gemcitabine or pegylated liposomal doxorubicin in platinum-resistant epithelial … Read more
By Hayley Virgil
Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.
The National Comprehensive Cancer Network (NCCN) has announced a significant … Read more
By Meg Tully
Rosemary Jemo volunteered for a blood test trial based on pioneering research from Johns Hopkins University because she thought it would be great if it could save lives.
The 71-year-old Pennsylvania hairdresser now believes that decision saved … Read more
